(Health Korea News / Lee Si-woo) Celltrion announced on the 24th that its domestic startup ‘Enterobiome’ was selected as the winner of the Kansai Life Science Accelerator Program (KLSAP) in Japan.
KLSAP is an accelerator program launched in 2020 by the Foundation for Biomedical Research and Innovation at Kobe (FBRI) and the city of Kobe to support startups that can operate globally, centered in the United States, and to vitalize the startup ecosystem in Kobe and the Kansai region.
KLSAP recently selected three companies, including Enterobiome, a domestic microbiome pharmaceutical development company, as the winning companies at ‘KLSAP 2024’ held recently.
According to Celltrion, the winning company will receive advice on clinical strategy and licensing in the U.S., business strategy consulting, and legal services related to establishing a U.S. subsidiary from BioLabs, a global accelerator. In particular, it will also receive support for partnership and investment attraction opportunities through networking with global pharmaceutical companies, venture capitals (VCs), etc. in the U.S.
Enterobiome, which was selected this time, is one of the first participating companies in the ‘Open Innovation’ program that Celltrion is conducting domestically to create a virtuous bio-cycle ecosystem. Celltrion is discovering and advancing the technology of startups with promising technologies such as Enterobiome in cooperation with Seoul Bio Hub and others in Korea, and is currently carrying out various support projects by completing the selection of companies up to the second round.
Participation in this ‘KLSAP 2024’ was also provided as a global networking opportunity for domestic companies that interacted with Celltrion. Through this, a domestic company was the first to compete with a Japanese company in Japan’s bio cluster program and achieved the result of being named one of the final winners.
Celltrion plans to continue operating various open innovation programs in the future and strengthen the capabilities of innovative startups at home and abroad through continuous and effective consulting and competitiveness enhancement. In addition, it plans to explore the possibility of cooperation with these companies on promising pipelines and platform technologies and realize the value of mutual growth.
A Celltrion official said, “The fact that a domestic startup was selected as an excellent company at this KLSAP 2024 is the result of enhancing corporate competitiveness and creating new cooperation opportunities through an active open innovation program.” He added, “We will continue to strengthen cooperation with promising domestic and foreign startups and actively create opportunities for joint growth such as pipeline and technology introduction.”
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
